SMAD3 and neoplasm: Figure 3A, the amount of tumor-infiltrated MDSC was enhanced by Smad3 knockout NK cell therapy from 17 to 23%, but not by Smad3 wild-type NK cell therapy nor GM-CSF-silenced Smad3 knockout NK cell therapy.